HC Wainwright & Co. Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $75
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and set a price target of $75.
August 19, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Aligos Therapeutics with a Buy rating and set a price target of $75.
The initiation of coverage with a Buy rating and a high price target of $75 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Aligos Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100